Demographic and selected clinical characteristics of 182 patients with POAML
| Characteristic . | Number . |
|---|---|
| Age >60 y | 100 (54.9%) |
| Median age (range), y | 63 (7-92) |
| Males/females | 72/110 |
| Race | |
| Non-Hispanic | 123 (67.5%) |
| Hispanic | 59 (32.9%) |
| Anatomical location | |
| Conjunctival | 51 (28%) |
| Orbit | 102 (56%) |
| Lacrimal gland | 29 (15.9%) |
| Bilateral disease | 28 (15.6%) |
| Ann Arbor stage/AJCC stage* | |
| I | 145 (79.6%) |
| T1 | 46 (31.7%) |
| T2 | 92 (63.4%) |
| T3 | 5 (3.4%) |
| T4 | 2 (1.3%) |
| II | 5 (2.7%) |
| III | 9 (4.9%) |
| IV | 16 (8.7%) |
| LDH above normal† | 11 (11.2%) |
| BM involvement‡ | 10 (8.6%) |
| IPI score | |
| 0 | 40 (22%) |
| 1 | 41 (22.5%) |
| 2 | 10 (5.4%) |
| 3 | 7 (3.8%) |
| 4 | 1 |
| NA | 83 (45.6%) |
| Characteristic . | Number . |
|---|---|
| Age >60 y | 100 (54.9%) |
| Median age (range), y | 63 (7-92) |
| Males/females | 72/110 |
| Race | |
| Non-Hispanic | 123 (67.5%) |
| Hispanic | 59 (32.9%) |
| Anatomical location | |
| Conjunctival | 51 (28%) |
| Orbit | 102 (56%) |
| Lacrimal gland | 29 (15.9%) |
| Bilateral disease | 28 (15.6%) |
| Ann Arbor stage/AJCC stage* | |
| I | 145 (79.6%) |
| T1 | 46 (31.7%) |
| T2 | 92 (63.4%) |
| T3 | 5 (3.4%) |
| T4 | 2 (1.3%) |
| II | 5 (2.7%) |
| III | 9 (4.9%) |
| IV | 16 (8.7%) |
| LDH above normal† | 11 (11.2%) |
| BM involvement‡ | 10 (8.6%) |
| IPI score | |
| 0 | 40 (22%) |
| 1 | 41 (22.5%) |
| 2 | 10 (5.4%) |
| 3 | 7 (3.8%) |
| 4 | 1 |
| NA | 83 (45.6%) |
IPI, International Prognostic Index; NA, not available.
Seven patients did not have staging information.
Analyzed in 98 patients.
BM was performed in 116 patients. From the 66 patients who did not undergo BM biopsy at presentation, 54 had Ann Arbor stage I disease, 1 had Ann Arbor stage II disease, and 4 had Ann Arbor stage III based on imaging studies.